Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Quince Therapeutics, Inc.

M&Asold assets or a business (SEC 8-K)14 Sept 2026

Quince Therapeutics, Inc.

14 Sept 2026: Sold assets or a business (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
14 Sept 2026
Ticker
QNCX
Role
Sold assets or a business
Sector
Pharma and biotech
Sic
2836
Items
2.01, 5.02, 9.01
Summary
On September 8, 2026, Quince Therapeutics, Inc. (the "Company") completed the sale of (i) all of the issued and outstanding equity interests of the subsidiary Quince Therapeutics SpA ("Quince SpA"), (ii) certain intellectual property owned by the Company relating to the Company's proprietary Autologous Intracellular Dr
Location
South San Francisco, CA
State
California
Country
United States
SEC CIK
1662774
Reference
0001193125-26-390652
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Quince Therapeutics, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Sold assets or a business

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.